Malaysian pharmaceutical company to produce COVID-19 adenoviral vector vaccine with Chinese technology (3)

(Xinhua) 10:06, September 10, 2021

A technician operates during a test run of the "fill and finish" process for CanSino vaccine at Solution Biologics factory in Kuala Lumpur, Malaysia, Sept. 8, 2021. Chinese company CanSino Biologics has helped Malaysia cross another milestone in vaccine manufacturing, this time by transferring technology to enable the local "fill and finish" of the COVID-19 vaccine based on the adenovirus platform. Malaysian pharmaceutical company Solution Biologics deputy group managing director Mohd Nazlee Kamal told Xinhua that close and friendly cooperation with CanSino has made the venture possible. (Photo by Chong Voon Chung/Xinhua)


(Web editor: Xia Peiyao, Liang Jun)


Related Stories